目录产品 » BDCA-2, His, Human
Manual
SDS
COAs

BDCA-2, His, Human

BDCA-2 is a novel type II C-type lectin specifically expressed by plasmacytoid dendritic cells (PDCs) that can internalize antigen for presentation to T cells. Furthermore, signaling via BDCA-2 may play a role in switching from interferon (IFN)-α/β-controlled to interleukin (IL)-12-controlled immune response pathways, as triggering of BDCA-2 potently inhibits secretion of IFN-α/β by PDCs and thereby promotes IL-12 p70 production in PDCs and other cells.
￥3500
Z05077-100

产品简介
Species Human
Protein Construction
His BDCA-2 (Phe46-Ile213)_x000D_
Accession # Q8WTT0-1
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 20.93 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 30-40 kDa based on Bis-Tris PAGE result.
Formulation Supplied as 0.22μm filtered solution in 20mM Tris, 500mM NaCl, 200mM L-arginine (pH 8.5).
Concentration Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford.
Storage & Stability This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles.
返回

技术背景
Target Background BDCA-2 is a novel type II C-type lectin specifically expressed by plasmacytoid dendritic cells (PDCs) that can internalize antigen for presentation to T cells. Furthermore, signaling via BDCA-2 may play a role in switching from interferon (IFN)-α/β-controlled to interleukin (IL)-12-controlled immune response pathways, as triggering of BDCA-2 potently inhibits secretion of IFN-α/β by PDCs and thereby promotes IL-12 p70 production in PDCs and other cells.
Synonyms BDCA-2; BDCA2; CLECSF11; CLECSF7; DLEC; HECL; CLEC4C; CD303;
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.